The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present invention relates to a method for solubilisation or hydrolysis of Municipal Solid Waste (MSW) with an enzyme blend and an enzyme composition for solubilization of Municipal Solid Waste (MSW), the enzyme composition comprising a cellulolytic background composition and a protease, lipase and/or beta-glucanase.

Genetically modified transgenic pigs or pig cells having at least one knocked out Transmembrane protease, serine (TMPRSS) gene. Expression of functional gene products of the at least one knocked out TMPRSS gene in the genetically modified transgenic pig or pig cells is reduced as compared to the non-genetically modified pig or pig cells. The at least one TMPRSS gene can be knocked out using CRISPR/Cas systems.

The present invention relates to the identification of peptides, and the corresponding proteins, that can be used in methods for the detection of autologous blood doping. More specifically, the invention relates to methods comprising tryptic digestion of samples of isolated red blood cell (RBC), specifically isolated RBC cytosol, followed by peptide mapping using liquid chromatography tandem-mass spectroscopy (LC-MS/MS). The methods according to the invention which enable detection of increased levels of certain peptides in samples from subjects that have been subjected to autologous blood doping, compared to samples from non-doped control subjects.

The present invention relates to polypeptide variants of porcine trypsin, to nucleic acid molecules encoding these variants, and to host cells comprising such nucleic acid molecules. It also relates to the use of these variants in methods for producing insulin. The invention further relates to the use of these variants as medicaments, as food ingredients, or as feed ingredients and to the use of these variants within a process of manufacturing a food ingredient or a feed ingredient.

An assay device including a loading zone for a sample that may contain an analyte, an activator in communication with the loading zone from which at least one activator is displaced by presence of the analyte, an amplifier in an inactive state in communication with the activator that becomes activated in the presence of the activator, a biomatrix barrier in communication with the activated amplifier that is degraded or modified by the activated amplifier, and an indicator responsive to the degradation or modification of the biomatrix barrier, which in turn reflects a concentration of the analyte in the sample loaded on the device. The selection of analyte or displacement of the activator by presence of the analyte may occur off-platform and/or may rely on use of non-covalent interactions. The activator may include an enzyme or other reagent that activates the amplifier. Also, associated methods.

A three-dimensional cell culture system that includes a keratin-based hydrogel precursor solution and a cell culture vessel is provided. The precursor solution includes solubilized keratin that has been functionalized to include a crosslinking moiety. The crosslinking moiety exhibits controllable crosslinking, e.g., a photopolymerizable crosslinking moiety. The crosslinking functionality is bonded to the keratin via cysteines following reduction of disulfide bonds of the native keratin. The precursor solution can be combined with cells to form a cell suspension that is disposed on a surface of the cell culture vessel. Alternatively, the cells can be added to a surface of a keratin-based hydrogel that has been formed on a surface of the cell culture vessel. The resulting three-dimensional cell culture system is a biomimetic/biologic, trypsin-degradable cell culture system for expansion of mammalian cells. The expanded cells are expected to possess a morphology similar to the primary cells prior to cultivation.

The present invention provides a polypeptide having protease activity for use in the treatment or prevention of coronavirus infection in a mammal. In particular, the invention relates to treatment or prevention of a coronavirus infection in a human, using trypsins.

Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.

Disclosed embodiments include devices and methods for shaping, bending, and/or volumetrically reducing rigid cartilaginous structures, such as hyaline cartilage in the septum. In the case of septal cartilage, shaping, bending, or reducing the cartilage would be useful for reducing nasal obstruction or to improve the cosmetic appearance of the nose.